MAGAGNOLI, LORENZA
MAGAGNOLI, LORENZA
Dipartimento di Scienze della Salute
Uremic Toxin‐Driven Vascular Calcification in Chronic Kidney Disease: Molecular Pathways and Integrated Phenotypes
2026 R. Fernando Rivera, M. Teresa Sciarrone Alibrandi, N. Edvige Foligno, L. Magagnoli, P. Ciceri, M. Cozzolino
Editorial Comment Beyond Biochemical Control: Reconsidering the Skeletal Impact of Calcimimetics in Hemodialysis
2026 M. Cozzolino, P. Ciceri, L. Magagnoli
Calcium Crystal Deposits in Kidney Allografts: The Interplay of PTH Levels and Phosphaturia
2026 S. Barbuto, G. Vischini, L. Magagnoli, M. Provenzano, G.M. Berti, A. Napoletano, M.G. Cozzolino, G. Comai, G. La Manna, G. Cianciolo
How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?
2026 L. Magagnoli, P. Ciceri, M. Cozzolino
Vascular Calcification in Advanced Chronic Kidney Disease: Epidemiology, Pathophysiology, and Treatment
2026 R. Fernando Rivera, M. Teresa Sciarrone Alibrandi, N. Edvige Foligno, L. Magagnoli, P. Ciceri, M. Cozzolino
Beyond traditional roles: vitamin D and erythropoietin as immune modulators in kidney diseases
2026 L. Magagnoli, S. Bin, P. Cravedi, M. Cozzolino
Hemoadsorption/hemodialysis: current evidence and outcome on uremic toxin removal and symptom improvement
2026 M. Cozzolino, L. Magagnoli, P. Ciceri
MCO Membranes and FGF-23: Advancing Dialysis Strategies for Better Outcomes?
2025 S. Barbuto, L. Magagnoli, G. Cianciolo, G. La Manna, M. Cozzolino, P. Ciceri
Calciprotein Particles in CKD: When Good Molecules Go Bad
2025 L. Magagnoli, M. Cozzolino
Association between Blood Flow Measured within 30 Days from Arteriovenous Access Creation and Thrombosis Risk
2025 G. Scherini, L. Magagnoli, A. Cara, G. Boni Brivio, I. Barbetta, L. Freni, U. Zoni, D. Curtò, A. Stucchi, M. Crippa, M. Cozzolino
Vitamin D: are all compounds equal?
2025 L. Magagnoli, M. Cassia, A. Galassi, P. Ciceri, E. Massò, R. Gelpi, J. Bover, M. Cozzolino
Critical evaluation of therapeutic targeting in chronic kidney disease: where do we stand 5 years on?
2025 M. Cozzolino, L. Magagnoli, P. Ciceri
Causal assessment of CKD-MBD biomarker alterations on CKD progression through a g-formula analysis in the EQUAL study
2025 L. Magagnoli, M. Cozzolino, F.J. Caskey, C. Torino, F.W. Dekker, M. Evans, M. Szymczak, C. Wanner, M. Pippias, C. Drechsler, A. Vilasi, E. Driehuis, P. Stenvinkel, V.S. Stel, K.J. Jager, N.C. Chesnaye
From Physicochemical Classification to Multidimensional Insights: A Comprehensive Review of Uremic Toxin Research
2025 M. Cozzolino, L. Magagnoli, P. Ciceri
Inibitori dell’enzima prolil-idrossilasi del fattore inducibile da ipossia: una nuova terapia per l’anemia nei pazienti con insufficienza renale cronica
2024 A. Stucchi, L. Magagnoli, A. Cara, M. Cozzolino
Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, Current treatments and investigational drugs
2024 L. Magagnoli, P. Ciceri, M. Cozzolino
Angiopoietin as A Novel Prognostic Marker in Kidney Disease
2024 A.B. Yildiz, S. Copur, C. Tanriover, F. Yavuz, S. Vehbi, A. Gaipov, L. Magagnoli, P. Ciceri, M. Cozzolino, M. Kanbay
Association between Chronic Kidney Disease-Mineral and Bone Disorder Biomarkers and Symptom Burden in Older Patients with Advanced Chronic Kidney Disease : Results from the EQUAL Study
2024 L. Magagnoli, M. Cozzolino, M. Evans, F.J. Caskey, F.W. Dekker, C. Torino, M. Szymczak, C. Drechsler, M. Pippias, A. Vilasi, R.J. Janse, M. Krajewska, V.S. Stel, K.J. Jager, N.C. Chesnaye
The open system of FGF-23 at the crossroad between additional P-lowering therapy, anemia and inflammation: how to deal with the intact and the C-terminal assays?
2023 L. Magagnoli, M. Cozzolino, A. Galassi
Choice of the Dialysis Modality: Practical Considerations
2023 M. Torreggiani, G.B. Piccoli, M.R. Moio, F. Conte, L. Magagnoli, P. Ciceri, M. Cozzolino